Quetiapine Tablet, Extended Release
Product Images NDC 70518-4430

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Quetiapine (NDC 70518-4430). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Mm2 (Quetiapine 50mg 70518 4430 01)

Quetiapine Tablet 50 mg Extended Release tablets image showing a label with quantity 30 tablets. Label includes usage warnings such as swallowing whole without splitting, crushing, or chewing. Labeler is RemedyRepack Inc., Indiana, PA, with manufacturer Unichem Labs Ltd., Goa, India. Storage instructions specify temperature ranges and keeping medication out of reach of children. The product is prescription only.*

FDA Label Image

Remedy_label (Remedy Label)

Label for Quetiapine extended-release tablets, 50 mg strength, quantity of 60. The label includes storage instructions, manufacturer information (Unichem Labs Ltd., Goa, India), and repackager details (RemedyRepack Inc., Indiana). It warns to swallow tablets whole without splitting or crushing and indicates oral administration.*

FDA Label Image

Image (C5ece454 9c87 42df A9f9 Fc9806d7c312 01)

Chemical structure of quetiapine fumarate, showing the quetiapine molecule and fumaric acid component typically present in the extended-release tablet formulation.*

FDA Label Image

Image (C5ece454 9c87 42df A9f9 Fc9806d7c312 02)

A line graph shows the proportion of patients with relapse (%) over time (months) comparing two treatments: PLA (placebo) and QTP XR (Quetiapine extended release). The graph plots relapse rates up to 7 months, illustrating a lower relapse proportion for QTP XR compared to placebo throughout the period.*

FDA Label Image

Image (C5ece454 9c87 42df A9f9 Fc9806d7c312 03)

A Kaplan-Meier curve graph showing the proportion of patients with relapse (%) on the y-axis against time (weeks) on the x-axis. The graph compares two groups: Quetiapine (QTP) plus Li/Val and placebo (PLA) plus Li/Val, illustrating relapse rates over approximately 100 weeks.*

FDA Label Image

Image (C5ece454 9c87 42df A9f9 Fc9806d7c312 04)

A Kaplan-Meier plot showing the proportion of patients with relapse (%) over time in weeks for two groups labeled QTP+ LIVAL and PLA+ LIVAL. The graph illustrates relapse rates over approximately 100 weeks, with the PLA+ LIVAL group showing a higher proportion of relapse compared to the QTP+ LIVAL group over time.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.